202 related articles for article (PubMed ID: 28880019)
1. Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations.
Simoens S; Huys I
Gene Ther; 2017 Sep; 24(9):539-541. PubMed ID: 28880019
[No Abstract] [Full Text] [Related]
2. Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy.
Pacione M; Siskind CE; Day JW; Tabor HK
J Neuromuscul Dis; 2019; 6(1):119-131. PubMed ID: 30594933
[TBL] [Abstract][Full Text] [Related]
3. Compilation of online resources of relevance to 'Spinraza and advanced therapies: a stakeholder special' issue of Gene Therapy.
Prakash V; Yáñez-Muñoz RJ
Gene Ther; 2017 Sep; 24(9):599. PubMed ID: 28963566
[No Abstract] [Full Text] [Related]
4. Nusinersen (Spinraza) for spinal muscular atrophy.
Med Lett Drugs Ther; 2017 Mar; 59(1517):50-52. PubMed ID: 28323809
[No Abstract] [Full Text] [Related]
5. Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy.
Burgart AM; Magnus D; Tabor HK; Paquette ED; Frader J; Glover JJ; Jackson BM; Harrison CH; Urion DK; Graham RJ; Brandsema JF; Feudtner C
JAMA Pediatr; 2018 Feb; 172(2):188-192. PubMed ID: 29228163
[TBL] [Abstract][Full Text] [Related]
6. New Therapy for Spinal Muscular Atrophy Offers Modest Bang for Pharamaceutical Buck.
Morrow T
Manag Care; 2017 Feb; 26(2):36-37. PubMed ID: 28271991
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides.
Aartsma-Rus A
Nucleic Acid Ther; 2017 Apr; 27(2):67-69. PubMed ID: 28346110
[No Abstract] [Full Text] [Related]
8. Nusinersen: A Treatment for Spinal Muscular Atrophy.
Claborn MK; Stevens DL; Walker CK; Gildon BL
Ann Pharmacother; 2019 Jan; 53(1):61-69. PubMed ID: 30008228
[TBL] [Abstract][Full Text] [Related]
9. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps.
Gidaro T; Servais L
Dev Med Child Neurol; 2019 Jan; 61(1):19-24. PubMed ID: 30221755
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological and clinical profile of spinal muscular atrophy (SMA) therapeutic drug nusinersen (Spinraza
Ohmura T; Saeki S; Ogiwara K; Tobita K; Ling Y; Torii S
Nihon Yakurigaku Zasshi; 2018; 152(3):147-159. PubMed ID: 30185733
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy.
Jalali A; Rothwell E; Botkin JR; Anderson RA; Butterfield RJ; Nelson RE
J Pediatr; 2020 Dec; 227():274-280.e2. PubMed ID: 32659229
[TBL] [Abstract][Full Text] [Related]
13. [Nusinersen in the treatment of spinal muscular atrophy].
Sinkó G; Kiss Z; Kalman B
Ideggyogy Sz; 2018 Mar; 71(3-04):90-94. PubMed ID: 29889467
[TBL] [Abstract][Full Text] [Related]
14. Spinraza-the patient perspective.
Madipalli S
Gene Ther; 2017 Sep; 24(9):501-502. PubMed ID: 28880018
[No Abstract] [Full Text] [Related]
15. Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers.
Chen E; Dixon S; Naik R; Noone JM; Buchenberger JD; Whitmire SM; Mills R; Arnold W
Muscle Nerve; 2021 Mar; 63(3):311-319. PubMed ID: 33184859
[TBL] [Abstract][Full Text] [Related]
16. Pre-Nusinersen Hospitalization Costs of Children With Spinal Muscular Atrophy.
Lee M; França UL; Graham RJ; McManus ML
Pediatr Neurol; 2019 Mar; 92():3-5. PubMed ID: 30591237
[No Abstract] [Full Text] [Related]
17. Nusinersen helps restore walking ability in childhood spinal muscular atrophy.
Sugimoto M; Aiba K; Koyama N; Yokochi K; Nishio H
Pediatr Int; 2019 Jul; 61(7):728-729. PubMed ID: 31290219
[No Abstract] [Full Text] [Related]
18. Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review.
Meylemans A; De Bleecker J
Acta Neurol Belg; 2019 Dec; 119(4):523-533. PubMed ID: 31388901
[TBL] [Abstract][Full Text] [Related]
19. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy.
Veerapandiyan A; Pal R; D'Ambrosio S; Young I; Eichinger K; Collins E; Westesson PL; Kwon J; Ciafaloni E
Neurology; 2018 Aug; 91(7):e620-e624. PubMed ID: 30006410
[TBL] [Abstract][Full Text] [Related]
20. Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience.
Veerapandiyan A; Eichinger K; Guntrum D; Kwon J; Baker L; Collins E; Ciafaloni E
Muscle Nerve; 2020 Feb; 61(2):222-226. PubMed ID: 31773738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
